Komori
ReproCELL (4978) · FactAnnual update to R&D expenses and headcount

Continued allocation of resources to research and development

First written in FY2017. 2 of 29 entries say "Restated". Latest entry: FY2026.

29entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2017 – FY20262017: 220172018: 420182019: 320192020: 420202021: 420212022: 320222023: 320232024: 320242025: 220252026: 12026
Same theme, other companies
Continuation of Company-wide R&D Activities and Resource InvestmentA theme 204 companies write about · 0 as a headwind · 217 as a tailwind

90 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 186 companies compared. The sentences above are computed from all 186.Comparing 200 of the theme's 219 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026Annual update to R&D expenses and headcountAnnual report

    「Total R&D expenses for the fiscal year were ¥627 million, representing a significant proportion, approximately 33%, of total selling, general and administrative expenses.」

    Updated the data to R&D expenses of ¥627 million, approximately 33% of SG&A expenses, and 21 employees engaged in R&D, while continuing to prioritize R&D as the highest-priority area.
  2. FY2026-H1Interim Update to R&D ExpenditureAnnual report

    「The amount spent on R&D during the six-month interim consolidated accounting period was ¥308 million. There were no material changes in the status of the Group's R&D activities during the six-month interim consolidated accounting period.」

    Reports R&D expenses of ¥308 million for the six-month interim consolidated accounting period and explains that there were no material changes in the status of the R&D activities.
  3. FY2025Annual update to R&D expenses and headcountAnnual report

    「Total R&D expenses for the fiscal year were ¥536 million, representing a significant proportion, approximately 30%, of total selling, general and administrative expenses.」

    Updated the data to R&D expenses of ¥536 million, approximately 30% of SG&A expenses, and 20 employees engaged in R&D, while continuing to prioritize R&D as the highest-priority area.
  4. FY2025-H1Interim Update to R&D ExpenditureAnnual report

    「The amount spent on R&D during the six-month interim consolidated accounting period was ¥236 million. There were no material changes in the status of the Group's R&D activities during the six-month interim consolidated accounting period.」

    Reports R&D expenses of ¥236 million for the six-month interim consolidated accounting period and explains that there were no material changes in the status of the R&D activities.
  5. FY2024Annual update to R&D expenses and headcountAnnual report

    「Total R&D expenses for the fiscal year were ¥384 million, representing a significant proportion, approximately 25%, of total selling, general and administrative expenses. … At the end of the fiscal year, the Group had 17 employees engaged in R&D.」

    Updated the data to R&D expenses of ¥384 million, approximately 25% of SG&A expenses, and 17 employees engaged in R&D. R&D expenses and headcount decreased from the previous fiscal year, but R&D continues to be the highest-priority area.
  6. FY2024-Q3Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first nine months of the fiscal year was ¥265 million.」

    Reports R&D expenses of ¥265 million for the first nine months of the fiscal year and explains that there were no material changes in the status of the R&D activities.
  7. FY2024-Q1Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first quarter of the fiscal year was ¥80 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the fiscal year.」

    States that R&D expenses for the first quarter of the fiscal year were ¥80 million and that there were no material changes in the status of the R&D activities.
  8. FY2023Annual update to R&D expenses and headcountAnnual report

    「Total R&D expenses for the fiscal year were ¥501 million, representing a significant proportion, approximately 33%, of total selling, general and administrative expenses. … At the end of the fiscal year, the Group had 20 employees engaged in R&D.」

    Updated the data to R&D expenses of ¥501 million, approximately 33% of SG&A expenses, and 20 employees engaged in R&D. R&D expenses decreased from ¥535 million, or approximately 37%, in the previous fiscal year, but R&D continues to be the highest-priority area.
  9. FY2023-Q3Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first nine months of the fiscal year was ¥337 million.」

    Reports R&D expenses of ¥337 million for the first nine months of the fiscal year and explains that there were no material changes in the status of the R&D activities.
  10. FY2023-Q2Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first six months of the fiscal year was ¥209 million.」

    Reports R&D expenses of ¥209 million for the first six months of the fiscal year and explains that there were no material changes in the status of the R&D activities.
  11. FY2023-Q1Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first quarter of the fiscal year was ¥100 million.」

    States that R&D expenses for the first quarter of the fiscal year were ¥100 million and that there were no material changes in the status of the R&D activities.
  12. FY2022-Q3Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first nine months of the fiscal year was ¥404 million.」

    States that R&D expenses for the first nine months of the fiscal year were ¥404 million and that there were no material changes in the status of the R&D activities.
  13. FY2022-Q2Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first six months of the fiscal year was ¥278 million.」

    States that R&D expenses for the first six months of the fiscal year were ¥278 million and that there were no material changes in the status of the R&D activities.
  14. FY2022-Q1Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first quarter of the fiscal year was ¥169 million.」

    Updated R&D expenses for the first quarter of the fiscal year to ¥169 million.
  15. FY2021Update to R&D expenses and headcountAnnual report

    「Total R&D expenses for the fiscal year were ¥662 million, representing a significant proportion, approximately 43%, of total selling, general and administrative expenses. … At the end of the fiscal year, the Group had 19 employees engaged in R&D.」

    Updated the data to R&D expenses of ¥662 million, approximately 43% of SG&A expenses, and 19 employees engaged in R&D.
  16. FY2021-Q3Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first nine months of the fiscal year was ¥495 million.」

    States that R&D expenses for the first nine months of the fiscal year were ¥495 million and that there were no material changes in the status of the R&D activities.
  17. FY2021-Q2Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first six months of the fiscal year was ¥298 million. There were no material changes in the status of the Group's R&D activities during the first six months of the fiscal year.」

    States that R&D expenses for the first six months of the fiscal year were ¥298 million and explains that there were no material changes in the status of the R&D activities.
  18. FY2021-Q1Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first quarter of the fiscal year was ¥118 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the fiscal year.」

    States that R&D expenses for the first quarter of the fiscal year were ¥118 million and explains that there were no material changes in the status of the R&D activities.
  19. FY2020Update to R&D expenses and headcountAnnual report

    「Total R&D expenses for the fiscal year were ¥454 million, representing a significant proportion, approximately 33%, of total selling, general and administrative expenses. … At the end of the fiscal year, the Group had 24 employees engaged in R&D.」

    Updated the current-period data: R&D expenses of ¥454 million, approximately 33% of SG&A expenses, and 24 employees engaged in R&D.
  20. FY2020-Q3Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first nine months of the fiscal year was ¥323 million. There were no material changes in the status of the Group's R&D activities during the first nine months of the fiscal year.」

    States that R&D expenses for the first nine months of the fiscal year were ¥323 million and explains that there were no material changes in the status of the R&D activities.
  21. FY2020-Q2Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first six months of the fiscal year was ¥194 million. There were no material changes in the status of the Group's R&D activities during the first six months of the fiscal year.」

    Reports R&D expenses of ¥194 million for the first six months of the fiscal year and explains that there were no material changes in the status of the R&D activities.
  22. FY2020-Q1Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first quarter of the fiscal year was ¥90 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the fiscal year.」

    States that R&D expenses for the first quarter of the fiscal year were ¥90 million and that there were no material changes in the R&D activities.
  23. FY2019-Q3Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first nine months of the fiscal year was ¥208 million. There were no material changes in the status of the Group's R&D activities during the first nine months of the fiscal year.」

    States that R&D expenses for the first nine months of the fiscal year were ¥208 million and that there were no material changes in the R&D activities.
  24. FY2019-Q2Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first six months of the fiscal year was ¥150 million. There were no material changes in the status of the Group's R&D activities during the first six months of the fiscal year.」

    States that R&D expenses for the first six months of the fiscal year were ¥150 million and that there were no material changes in the R&D activities.
  25. FY2019-Q1Update to Research and Development ExpensesAnnual report

    「The amount spent on R&D during the first quarter of the fiscal year was ¥81 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the fiscal year.」

    States that R&D expenses for the quarter were ¥81 million and that there were no material changes in the R&D activities.
  26. FY2018Update to R&D expenses and headcountAnnual report

    「Total R&D expenses for the fiscal year were ¥191 million, representing a significant proportion, approximately 14%, of total selling, general and administrative expenses. … At the end of the fiscal year, the Group had 17 employees engaged in R&D.」

    R&D expenses decreased from ¥276 million to ¥191 million and the number of employees engaged in R&D decreased from 36 to 17, while the policy of continuing to prioritize R&D was maintained.
  27. FY2018-Q3RestatedAnnual report

    「The amount spent on R&D during the first nine months of the fiscal year was ¥122.171 million. There were no material changes in the status of the Group's R&D activities during the first nine months of the fiscal year.」

    States that R&D expenses for the first nine months of the fiscal year were ¥122.171 million and that there were no material changes in the R&D activities.
  28. FY2018-Q1RestatedAnnual report

    「The amount spent on R&D during the first quarter of the fiscal year was ¥39.512 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the fiscal year.」

    States that R&D expenses for the quarter were ¥39.512 million and that there were no material changes in the R&D activities.
  29. FY2017First statedAnnual report

    「Total R&D expenses for the fiscal year were ¥276 million, representing a significant proportion, approximately 18%, of total selling, general and administrative expenses. … At the end of the fiscal year, the Group had 36 employees engaged in R&D.」

    Recorded the R&D base data: R&D expenses of ¥276 million, approximately 18% of SG&A expenses, and 36 employees engaged in R&D.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for ReproCELL yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Continued allocation of resources to research and development | ReproCELL Incorporated (4978) | Komori